Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare's reimbursement policy

被引:6
作者
Li, Minghui [1 ]
Schulz, Richard [2 ]
Chisholm-Burns, Marie [1 ]
Wang, Junling [1 ]
Lu, Z. Kevin [2 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Memphis, TN USA
[2] Univ South Carolina, Coll Pharm, Columbia, SC 29208 USA
关键词
CLINICAL-PRACTICE GUIDELINE; NATIONAL COVERAGE DETERMINATION; CHEMOTHERAPY-INDUCED ANEMIA; CELL LUNG-CANCER; DOUBLE-BLIND; EPOETIN-ALPHA; DARBEPOETIN-ALPHA; AMERICAN-SOCIETY; SAFETY; ONCOLOGY;
D O I
10.18553/jmcp.2020.26.11.1477
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Because of increasing safety concerns related to erythropoiesis-stimulating agents (ESAs), the Centers for Medicare & Medicaid Services issued a Medicare reimbursement policy change regarding these medications in cancer patients. However, the policy established an absolute hemoglobin or hematocrit threshold to qualify for reasonable use but did not take the effect of gender and racial/ethnic differences in hemoglobin levels into consideration. OBJECTIVE: To examine disparities in the use of ESAs and blood transfusions after the Medicare policy change. METHODS: This study was an exploratory treatment effectiveness study and used the SEER-Medicare linked database. The treatment group was composed of cancer patients, whereas the control group was composed of chronic kidney disease patients. An interrupted time series design was used to examine the effect of the Medicare policy change on the use of ESAs and blood transfusions in different gender and racial/ethnic groups. RESULTS: The Medicare reimbursement policy change had an immediate effect on reducing the use of ESAs by 50% and increasing the use of blood transfusions by 10%. The immediate effect of the policy change on the monthly utilization of ESAs was 2 times greater in females (60% reduction) than males (30% reduction). Females had a 10% immediate increase in the monthly utilization of blood transfusions after the policy change. The policy change had the same immediate effect of a 50% reduction on the use of ESAs for Whites, African Americans/Blacks, and Latinos. African Americans/Blacks had a 50% immediate increase in the monthly utilization of blood transfusions after the policy change. CONCLUSIONS: Gender and racial/ethnic disparities were associated with the Medicare reimbursement policy change in the use of ESAs and blood transfusions. Thus, future policy considerations should keep biologic differences across gender and racial/ethnic groups in mind.
引用
收藏
页码:1477 / 1486
页数:10
相关论文
共 45 条
  • [1] Antos J, 2008, AM HEALTH DRUG BENEF, V1, P13
  • [2] Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: Perspectives and issues on policy-guided health care
    Arbuckle, Rebecca B.
    Griffith, Niesha L.
    Iacovelli, Lew M.
    Johnson, Philip E.
    Jorgenson, James A.
    Kloth, Dwight D.
    Lucarelli, Charles D.
    Muller, Raymond J.
    [J]. PHARMACOTHERAPY, 2008, 28 (05): : 1S - 15S
  • [3] Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients
    Arneson, Thomas J.
    Li, Shuling
    Gilbertson, David T.
    Bridges, Kenneth R.
    Acquavella, John F.
    Collins, Allan J.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (08) : 857 - 864
  • [4] The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?
    Beutler, E
    Waalen, J
    [J]. BLOOD, 2006, 107 (05) : 1747 - 1750
  • [5] The continuing risk of transfusion-transmitted infections
    Blajchman, Morris A.
    Vamvakas, Eleftherios C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (13) : 1303 - 1305
  • [6] Erythropoietin or Darbepoetin for patients with cancer
    Bohlius, J.
    Wilson, J.
    Seidenfeld, J.
    Piper, M.
    Schwarzer, G.
    Sandercock, J.
    Trelle, S.
    Weingart, O.
    Bayliss, S.
    Brunskill, S.
    Djulbegovic, B.
    Benett, C. L.
    Langensiepen, S.
    Hyde, C.
    Engert, E.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (03):
  • [7] Bohlius J., 2004, Cochrane Database Syst. Rev, pCD003407, DOI [10.1002/14651858.CD003407.pub2, DOI 10.1002/14651858.CD003407.PUB2]
  • [8] Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
    Bohlius, Julia
    Wilson, Jayne
    Seidenfeld, Jerome
    Piper, Margaret
    Schwarzer, Guido
    Sandercock, Josie
    Trelle, Sven
    Weingart, Olaf
    Bayliss, Sue
    Djulbegovic, Benjamin
    Bennett, Charles L.
    Langensiepen, Simon
    Hyde, Chris
    Engert, Andreas
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (10): : 708 - 714
  • [9] Bacterial contamination of blood components
    Brecher, ME
    Hay, SN
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2005, 18 (01) : 195 - +
  • [10] Emily Cooley Lecture 2002: Transfusion safety in the hospital
    Dzik, WH
    [J]. TRANSFUSION, 2003, 43 (09) : 1190 - 1199